{"id":7068,"date":"2019-11-18T14:41:08","date_gmt":"2019-11-18T22:41:08","guid":{"rendered":"https:\/\/2020dev.rakuten-med.com\/?post_type=news&#038;p=7068"},"modified":"2022-07-25T23:01:02","modified_gmt":"2022-07-26T06:01:02","slug":"rakuten-anti-cancer-therapy-candidate-to-activate-immune-system-response","status":"publish","type":"stories","link":"https:\/\/rakuten-med.com\/us\/news\/stories\/2019\/11\/18\/7068\/","title":{"rendered":"Rakuten anti-cancer therapy candidate to activate immune system response"},"content":{"rendered":"<p>BioSpectrum Asia | November 11, 2019: Rakuten Medical, Inc. (RMI) a clinical-stage, global biotechnology company with offices in the U.S., Japan, Taiwan, Germany and the Netherlands, developing precision-targeted cancer therapies based on Rakuten Medical&#8217;s Illuminox\u2122, its proprietary, anti-cancer treatment platform, introduced new preclinical data suggesting CD25 photoimmunotherapy (PIT) treatment, combined with an anti-PD1 therapy, may stimulate the immune system, and lead to a synergistic, anti-cancer activity in targeted tumors.<\/p>\n<p>&#8220;These exciting data suggests that anti-CD25 photoimmunotherapy may alter the immune tumor environment and unlock the potential of combination immunotherapies for patients living with certain types of cancers for which there are few treatment options,&#8221; said Miguel Garcia-Guzman, Ph.D., Vice Chairman and Chief Scientific Officer at Rakuten Medical. &#8220;We are committed to harnessing the full potential of the immune system through modulation of the cancer tumor environment, and these results support our clinical development program based on our anti-cancer treatment platform, Rakuten Medical&#8217;s Illuminox\u2122.&#8221;<\/p>\n<p><a href=\"https:\/\/www.biospectrumasia.com\/news\/26\/14874\/rakuten-anti-cancer-therapy-candidate-to-activate-immune-system-response.html\" target=\"_blank\" rel=\"noopener noreferrer\">Read the Full Article<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BioSpectrum Asia | November 11, 2019: Rakuten Medical, Inc. (RMI) a clinical-stage, global biotechnology company with offices in the U.S., [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"template":"","meta":{"_acf_changed":false,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":""},"class_list":{"0":"post-7068","1":"stories","2":"type-stories","3":"status-publish","5":"entry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rakuten anti-cancer therapy candidate to activate immune system response - Rakuten Medical - To conquer cancer.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/rakuten-med.com\/us\/news\/stories\/2019\/11\/18\/7068\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rakuten anti-cancer therapy candidate to activate immune system response - Rakuten Medical - To conquer cancer.\" \/>\n<meta property=\"og:description\" content=\"BioSpectrum Asia | November 11, 2019: Rakuten Medical, Inc. (RMI) a clinical-stage, global biotechnology company with offices in the U.S., [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/rakuten-med.com\/us\/news\/stories\/2019\/11\/18\/7068\/\" \/>\n<meta property=\"og:site_name\" content=\"Rakuten Medical - To conquer cancer.\" \/>\n<meta property=\"article:modified_time\" content=\"2022-07-26T06:01:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2021\/02\/RakutenMedical_KV.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1500\" \/>\n\t<meta property=\"og:image:height\" content=\"900\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/stories\\\/2019\\\/11\\\/18\\\/7068\\\/\",\"url\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/stories\\\/2019\\\/11\\\/18\\\/7068\\\/\",\"name\":\"Rakuten anti-cancer therapy candidate to activate immune system response - Rakuten Medical - To conquer cancer.\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/#website\"},\"datePublished\":\"2019-11-18T22:41:08+00:00\",\"dateModified\":\"2022-07-26T06:01:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/stories\\\/2019\\\/11\\\/18\\\/7068\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/stories\\\/2019\\\/11\\\/18\\\/7068\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/news\\\/stories\\\/2019\\\/11\\\/18\\\/7068\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rakuten anti-cancer therapy candidate to activate immune system response\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/\",\"name\":\"Rakuten Medical - To conquer cancer.\",\"description\":\"Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox\u2122TM technology platform. We are committed to our mission to conquer cancer and aim to achieve a society where cancer patients can lead fulfilling lives.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/rakuten-med.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rakuten anti-cancer therapy candidate to activate immune system response - Rakuten Medical - To conquer cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/rakuten-med.com\/us\/news\/stories\/2019\/11\/18\/7068\/","og_locale":"en_US","og_type":"article","og_title":"Rakuten anti-cancer therapy candidate to activate immune system response - Rakuten Medical - To conquer cancer.","og_description":"BioSpectrum Asia | November 11, 2019: Rakuten Medical, Inc. (RMI) a clinical-stage, global biotechnology company with offices in the U.S., [&hellip;]","og_url":"https:\/\/rakuten-med.com\/us\/news\/stories\/2019\/11\/18\/7068\/","og_site_name":"Rakuten Medical - To conquer cancer.","article_modified_time":"2022-07-26T06:01:02+00:00","og_image":[{"width":1500,"height":900,"url":"https:\/\/rakuten-med.com\/us\/wp-content\/uploads\/sites\/6\/2021\/02\/RakutenMedical_KV.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/rakuten-med.com\/us\/news\/stories\/2019\/11\/18\/7068\/","url":"https:\/\/rakuten-med.com\/us\/news\/stories\/2019\/11\/18\/7068\/","name":"Rakuten anti-cancer therapy candidate to activate immune system response - Rakuten Medical - To conquer cancer.","isPartOf":{"@id":"https:\/\/rakuten-med.com\/us\/#website"},"datePublished":"2019-11-18T22:41:08+00:00","dateModified":"2022-07-26T06:01:02+00:00","breadcrumb":{"@id":"https:\/\/rakuten-med.com\/us\/news\/stories\/2019\/11\/18\/7068\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/rakuten-med.com\/us\/news\/stories\/2019\/11\/18\/7068\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/rakuten-med.com\/us\/news\/stories\/2019\/11\/18\/7068\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/rakuten-med.com\/us\/"},{"@type":"ListItem","position":2,"name":"Rakuten anti-cancer therapy candidate to activate immune system response"}]},{"@type":"WebSite","@id":"https:\/\/rakuten-med.com\/us\/#website","url":"https:\/\/rakuten-med.com\/us\/","name":"Rakuten Medical - To conquer cancer.","description":"Rakuten Medical, Inc. is a global biotechnology company developing precision, cell-targeting investigational therapies on its Alluminox\u2122TM technology platform. We are committed to our mission to conquer cancer and aim to achieve a society where cancer patients can lead fulfilling lives.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/rakuten-med.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/stories\/7068","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/stories"}],"about":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/types\/stories"}],"author":[{"embeddable":true,"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/users\/2"}],"wp:attachment":[{"href":"https:\/\/rakuten-med.com\/us\/wp-json\/wp\/v2\/media?parent=7068"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}